LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) ...

Related Keywords

United States ,United Arab Emirates ,Canada ,Denmark ,United Kingdom ,Ballerup ,Hovedstaden ,Antara ,Aceh ,Indonesia ,Great Britain ,Jonathan Silverberg ,Leo Pharma ,Anders Kronborg ,Pia Beltr ,David Patti ,National Eczema Association ,Drug Administration ,Adbrytm Advocatetm Program ,European Union ,Global Commercial Communications ,Global Product Communications ,Health Sciences ,United Arab ,Business Wire ,Chief Financial Officer ,Acting Chief Executive Officer ,Associate Professor ,George Washington University School ,Julie Block ,National Eczema ,Director Global Commercial Communications ,